Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sabizabulin (ABI-231) is a potent, orally bioavailable α- and β-tubulin inhibitor that is active against melanoma and prostate cancer cell lines. Sabizabulin inhibits tumor growth and metastatic phenotypes of cervical cancer cells by targeting HPV E6 and E7 and is also being studied in prostate cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 140 € | In Stock | |
2 mg | 207 € | In Stock | |
5 mg | 353 € | In Stock | |
10 mg | 547 € | In Stock | |
25 mg | 880 € | In Stock | |
50 mg | 1.197 € | In Stock | |
100 mg | 1.596 € | In Stock | |
500 mg | 3.220 € | In Stock |
Description | Sabizabulin (ABI-231) is a potent, orally bioavailable α- and β-tubulin inhibitor that is active against melanoma and prostate cancer cell lines. Sabizabulin inhibits tumor growth and metastatic phenotypes of cervical cancer cells by targeting HPV E6 and E7 and is also being studied in prostate cancer. |
In vitro | METHODS: BT474 and SKBR3 cells were treated with Sabizabulin (ABI-231) (4, 8, 12, 16 nM), and cell growth inhibition was measured by MTS assay. RESULTS Sabizabulin (ABI-231) significantly inhibited the growth of BT474 and SKBR3 cells in a concentration-dependent manner with IC50 values of 9.07 and 8.18 nM, respectively, and had low cytotoxicity. [1] |
In vivo | METHODS: Sabizabulin (ABI-231) (17 mg/kg/20 mg/kg, oral, three weeks) was used to treat BT474 xenograft/HCI-12 PDX model mice and its therapeutic effect was observed. RESULTS Sabizabulin (ABI-231) significantly reduced the tumor volume and tumor wet weight of terminal BT474 xenograft mice, inhibited tumor growth and suppressed lung metastasis in HCI-12 PDX model mice. [1] |
Alias | VERU-111, ABI-231 |
Molecular Weight | 377.39 |
Formula | C21H19N3O4 |
Cas No. | 1332881-26-1 |
Smiles | COc1cc(cc(OC)c1OC)C(=O)c1c[nH]c(n1)-c1c[nH]c2ccccc12 |
Relative Density. | 1.306 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (132.49 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.